Affinia Therapeutics

Jan 09, 2025

Affinia Therapeutics Announces Development Candidate for BAG3 DCM and Completion of Pre-IND Meeting with the FDA

Nov 13, 2024

Affinia Therapeutics and Forge Biologics Announce AAV cGMP Manufacturing Partnership to Advance Affinia Therapeutics' Pipeline of Next-Generation Gene Therapies to the Clinic

Oct 22, 2024

Affinia Therapeutics to Highlight New Data on Genetic Cardiomyopathy Programs and BBB-Penetrant Capsids Leveraging Novel Receptors at the European Society of Gene & Cell Therapy 2024 31st Annual Congress

Sep 23, 2024

Affinia Therapeutics to Participate in Upcoming Investor and Industry Conferences

May 28, 2024

Affinia Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference

May 10, 2024

Affinia Therapeutics Presents Preclinical Data for Genetic Cardiomyopathy and Sporadic ALS Programs with Novel Cardiotropic and BBB-Penetrant AAV Capsids at the American Society of Gene & Cell Therapy 2024 Annual Meeting

Apr 22, 2024

Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gene & Cell Therapy 2024 Annual Meeting